PebblePilot
Well-known member
Groundbreaking Blood Test Could Revolutionize Cancer Diagnostics, Study Finds
A new blood test has shown promising results in identifying cancerous DNA fragments that have broken off from tumors and are circulating in the bloodstream. The test, known as Galleri, has been developed by American pharmaceutical firm Grail and is currently being trialed by the NHS.
The study, which followed 25,000 adults in North America over a year, found that nearly one in 100 tested positive for cancer, with an impressive 62% of these cases later confirmed. The test was able to detect fragments of DNA from more than 50 types of cancer, including three-quarters that do not have any screening program.
The Galleri test works by detecting the presence of cancer-specific DNA fragments in blood samples, which can be used to identify the type and origin of cancer. In nine out of 10 cases, the test correctly identified the origin of the cancer.
While the results are exciting, scientists caution that further research is needed to determine whether the test reduces deaths from cancer. The NHS will soon begin a three-year trial involving 140,000 patients in England, with the aim of extending the test to an additional one million people if successful.
The potential impact of this test cannot be overstated, as many cancers are currently diagnosed at advanced stages when treatment options are limited. Early detection through screening programs can significantly improve treatment outcomes and survival rates.
However, there is also a risk of overdiagnosis, where cancerous tumors are detected that may not have caused harm or will not progress to life-threatening disease. It's essential that further research focuses on determining the benefits and risks of this test in reducing mortality from cancer.
As Dr Nima Nabavizadeh, lead researcher, emphasized, "This data shows us that we can fundamentally change our approach to cancer screening." If successful, the Galleri test could revolutionize the way cancer is diagnosed and treated, offering new hope for patients and their families.
A new blood test has shown promising results in identifying cancerous DNA fragments that have broken off from tumors and are circulating in the bloodstream. The test, known as Galleri, has been developed by American pharmaceutical firm Grail and is currently being trialed by the NHS.
The study, which followed 25,000 adults in North America over a year, found that nearly one in 100 tested positive for cancer, with an impressive 62% of these cases later confirmed. The test was able to detect fragments of DNA from more than 50 types of cancer, including three-quarters that do not have any screening program.
The Galleri test works by detecting the presence of cancer-specific DNA fragments in blood samples, which can be used to identify the type and origin of cancer. In nine out of 10 cases, the test correctly identified the origin of the cancer.
While the results are exciting, scientists caution that further research is needed to determine whether the test reduces deaths from cancer. The NHS will soon begin a three-year trial involving 140,000 patients in England, with the aim of extending the test to an additional one million people if successful.
The potential impact of this test cannot be overstated, as many cancers are currently diagnosed at advanced stages when treatment options are limited. Early detection through screening programs can significantly improve treatment outcomes and survival rates.
However, there is also a risk of overdiagnosis, where cancerous tumors are detected that may not have caused harm or will not progress to life-threatening disease. It's essential that further research focuses on determining the benefits and risks of this test in reducing mortality from cancer.
As Dr Nima Nabavizadeh, lead researcher, emphasized, "This data shows us that we can fundamentally change our approach to cancer screening." If successful, the Galleri test could revolutionize the way cancer is diagnosed and treated, offering new hope for patients and their families.